CLAIMS

1. An antibody that binds Protein S, wherein the antibody is an inhibitor of the cofactor activity of Protein S for activated Protein C (APC), an inhibitor of the cofactor activity of Protein S for tissue factor pathway inhibitor (TFPI), an inhibitor of the cofactor activity of Protein S for both APC and TFPI, or is capable of promoting coagulation and/or modulating a component in the coagulation cascade and wherein the antibody is human, humanized, or chimeric.
2. The antibody of claim 1, wherein the capability of the antibody for inhibiting the cofactor activity of Protein S for TFPI is negligible.
3. The antibody of claim 1, wherein the capability of the antibody for inhibiting the cofactor activity of Protein S for APC is negligible.
4. The antibody of claim 1, wherein the antibody binds to the C-terminus or the N-terminus of Protein S.
5. The antibody of claim 1, wherein the antibody binds to a thrombin-sensitive region, an EGF region, or a SHBG region of the Protein S.
6. The antibody of claim 1, wherein the antibody is capable of promoting generation of a marker associated with coagulation activity, wherein the marker of coagulation activity is one or more of the following: thrombin generation, D-dimer levels and fibrin generation.
7. The antibody of claim 1, wherein activity of the antibody is dose-dependent.
8. The antibody of claim 1, wherein the binding affinity of the antibody to Protein S is calcium-dependent.
9. The antibody of claim 1, wherein the antibody binds to free Protein S or complexed Protein S.
10. The antibody of claim 1, wherein the Protein S is complexed with C4BP or TFPI.
11. The antibody of claim 1, wherein the antibody is a monoclonal antibody.
12. The antibody of claim 1, wherein the antibody is a full-length antibody.
13. The antibody of claim 1, wherein the antibody is an antibody fragment.
14. The antibody of claim 1, wherein the antibody is a humanized antibody.
15. The antibody of claim 1, wherein the antibody comprises a Fc domain.
16. The antibody of claim 15, wherein the Fc domain is human, wherein the human Fc domain is IgG1, IgG2, IgG3, or IgG4.

17. The antibody of claim 16, wherein the Fc domain of the antibody is human IgG4, optionally SEQ ID NO: 218, and comprises at least one amino acid substitution at a position selected from the group consisting of: 215, 221, 222, 228, 234, 235, 236, 239, 240, 241, 243, 244, 245, 247, 250, 252, 254, 256, 262, 263, 264, 265, 266, 267, 268, 269, 270, 292, 296, 297, 298, 299, 300, 305, 313, 324, 325, 326, 327, 328, 329, 330, 332, 333, 334, 345, 396, 428, 430, 433, 434, and 440, or comprises one or more of the substitutions selected from the group consisting of T250Q/M428L, M252Y/S254T/T256E, M428L/N434S, S267E/L328F, N325S/L328F, and H433K/N434F, wherein the position numbers of the amino acid residues are of the EU numbering scheme.

18. The antibody of claim 1, wherein the antibody is conjugated.

19. The antibody of claim 18, wherein the antibody is conjugated to a label.

20. The antibody of claim 1, wherein the antibody comprises any one or more of the amino acid sequences of the complementarity determining region (CDR) sequences provided in Tables 1A, 1B, 1C, 2A, 2B, and 2C.

21. The Protein S antibody of claim 1, wherein the antibody comprises the light and heavy variable chain amino acid sequence of any one of the amino acid sequence combinations provided in Table 4C, or a light and heavy variable chain amino acid sequence with at least 80% sequence identity thereto.

22. The Protein S antibody of claim 1, wherein a light chain of the antibody comprises the amino acid sequence of SEQ ID NO: 214 or SEQ ID NO: 215.

23. A pharmaceutical composition comprising the antibody of claim 1, and optionally a pharmaceutically acceptable excipient.

24. A nucleic acid encoding for the antibody of claim 1.

25. A vector comprising the nucleic acid of claim 24.

26. An *in vitro* method of promoting the coagulation of blood, comprising contacting the antibody of claim 1 with a blood sample.

27. Use of the pharmaceutical composition of claim 23, in the manufacture of a medicament for promoting the coagulation of blood in a subject in need thereof.

28. Use of the pharmaceutical composition of claim 23, in the manufacture of a medicament for promoting the generation of thrombin in a subject in need thereof.

29. The use of claim 28, wherein the subject has a coagulation factor deficiency, von Willebrand disease, or a platelet disorder, and the antibody restores or promotes the generation of thrombin.

30. Use of the pharmaceutical composition of claim 23, in the manufacture of a medicament for treating a condition in a subject in need thereof, wherein the condition is selected from the group consisting of: bleeding disorders, platelet disorders, trauma, and bleeding resulting from a surgery or a medical procedure.

31. The use of claim 30, wherein the subject suffers from two or more conditions selected from the group consisting of: bleeding disorders, platelet disorders, trauma, and bleeding resulting from a surgery or a medical procedure.